Preclinical metabolism of LB42908, a novel farnesyl transferase inhibitor, and its effects on the cytochrome P450 isozyme activities.

@article{Kim2012PreclinicalMO,
  title={Preclinical metabolism of LB42908, a novel farnesyl transferase inhibitor, and its effects on the cytochrome P450 isozyme activities.},
  author={Ho Jun Kim and Sung-Hak Lee and Jong-Sung Koh and Sun Hwa Lee},
  journal={Bioorganic & medicinal chemistry letters},
  year={2012},
  volume={22 9},
  pages={3067-71}
}
Metabolism of LB42908, a novel farnesyl transferase inhibitor, was investigated for preclinical development. In vitro hepatic metabolism of LB42908 gave rise to at least 9 metabolites via phase I biotransformation pathways, which were characterized by HPLC-UV, LC-MS, and LC-MS/MS analyses. N-Dealkylation was shown to be a major phase I metabolic pathway… CONTINUE READING